These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 29530712)

  • 1. Genetic disruption of the nuclear receptor Nur77 (Nr4a1) in rat reduces dopamine cell loss and l-Dopa-induced dyskinesia in experimental Parkinson's disease.
    Rouillard C; Baillargeon J; Paquet B; St-Hilaire M; Maheux J; Lévesque C; Darlix N; Majeur S; Lévesque D
    Exp Neurol; 2018 Jun; 304():143-153. PubMed ID: 29530712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gadd45β ameliorates L-DOPA-induced dyskinesia in a Parkinson's disease mouse model.
    Park HY; Ryu YK; Kim YH; Park TS; Go J; Hwang JH; Choi DH; Rhee M; Lee CH; Kim KS
    Neurobiol Dis; 2016 May; 89():169-79. PubMed ID: 26875664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Striatal mRNA expression patterns underlying peak dose L-DOPA-induced dyskinesia in the 6-OHDA hemiparkinsonian rat.
    Smith LM; Parr-Brownlie LC; Duncan EJ; Black MA; Gemmell NJ; Dearden PK; Reynolds JN
    Neuroscience; 2016 Jun; 324():238-51. PubMed ID: 26968766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease.
    Sellnow RC; Steece-Collier K; Altwal F; Sandoval IM; Kordower JH; Collier TJ; Sortwell CE; West AR; Manfredsson FP
    J Neurosci; 2020 Apr; 40(18):3675-3691. PubMed ID: 32238479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GABA storage and release in the medial globus pallidus in L-DOPA-induced dyskinesia priming.
    Nishijima H; Mori F; Arai A; Zhu G; Wakabayashi K; Okada M; Ueno S; Ichinohe N; Suzuki C; Kon T; Tomiyama M
    Neurobiol Dis; 2020 Sep; 143():104979. PubMed ID: 32590036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuated dopaminergic neurodegeneration and motor dysfunction in hemiparkinsonian mice lacking the α5 nicotinic acetylcholine receptor subunit.
    Leino S; Koski SK; Hänninen R; Tapanainen T; Rannanpää S; Salminen O
    Neuropharmacology; 2018 Aug; 138():371-380. PubMed ID: 29940207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the atypical vesicular glutamate transporter VGLUT3 in l-DOPA-induced dyskinesia.
    Gangarossa G; Guzman M; Prado VF; Prado MA; Daumas S; El Mestikawy S; Valjent E
    Neurobiol Dis; 2016 Mar; 87():69-79. PubMed ID: 26711621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
    McCreary AC; Varney MA; Newman-Tancredi A
    Neuropharmacology; 2016 Jun; 105():651-660. PubMed ID: 26777281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
    Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
    Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-γ Involvement in the Neuroinflammation Associated with Parkinson's Disease and L-DOPA-Induced Dyskinesia.
    Ferrari DP; Bortolanza M; Del Bel EA
    Neurotox Res; 2021 Jun; 39(3):705-719. PubMed ID: 33687725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nociceptive Response to L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats.
    Nascimento GC; Bariotto-Dos-Santos K; Leite-Panissi CRA; Del-Bel EA; Bortolanza M
    Neurotox Res; 2018 Nov; 34(4):799-807. PubMed ID: 29611150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats.
    Bishop C; George JA; Buchta W; Goldenberg AA; Mohamed M; Dickinson SO; Eissa S; Eskow Jaunarajs KL
    Eur J Neurosci; 2012 Sep; 36(6):2839-48. PubMed ID: 22762478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitogen- and stress-activated protein kinase 1 is required for specific signaling responses in dopamine-denervated mouse striatum, but is not necessary for L-DOPA-induced dyskinesia.
    Alcacer C; Charbonnier-Beaupel F; Corvol JC; Girault JA; Hervé D
    Neurosci Lett; 2014 Nov; 583():76-80. PubMed ID: 25233866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher free D-aspartate and N-methyl-D-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-induced dyskinesia.
    Errico F; Bonito-Oliva A; Bagetta V; Vitucci D; Romano R; Zianni E; Napolitano F; Marinucci S; Di Luca M; Calabresi P; Fisone G; Carta M; Picconi B; Gardoni F; Usiello A
    Exp Neurol; 2011 Dec; 232(2):240-50. PubMed ID: 21946266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human COMT over-expression confers a heightened susceptibility to dyskinesia in mice.
    Solís O; García-Montes JR; Garcia-Sanz P; Herranz AS; Asensio MJ; Kang G; Hiroi N; Moratalla R
    Neurobiol Dis; 2017 Jun; 102():133-139. PubMed ID: 28315782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine D3 Receptor Modulates l-DOPA-Induced Dyskinesia by Targeting D1 Receptor-Mediated Striatal Signaling.
    Solís O; Garcia-Montes JR; González-Granillo A; Xu M; Moratalla R
    Cereb Cortex; 2017 Jan; 27(1):435-446. PubMed ID: 26483399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enkephalin and dynorphin neuropeptides are differently correlated with locomotor hypersensitivity and levodopa-induced dyskinesia in parkinsonian rats.
    Sgroi S; Capper-Loup C; Paganetti P; Kaelin-Lang A
    Exp Neurol; 2016 Jun; 280():80-8. PubMed ID: 27072528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormal Cortico-Basal Ganglia Neurotransmission in a Mouse Model of l-DOPA-Induced Dyskinesia.
    Dwi Wahyu I; Chiken S; Hasegawa T; Sano H; Nambu A
    J Neurosci; 2021 Mar; 41(12):2668-2683. PubMed ID: 33563724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Cenci MA
    Amino Acids; 2002; 23(1-3):105-9. PubMed ID: 12373525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.